Searched for
ZITA MET
Glenmark Pharmaceuticals rises 5% on launching first 3-drug FDC for type-2 diabetes in India“This FDC has been launched under the brand name Zita®-PioMet,” the company said in a BSE filing. “This offers patients with Type 2 diabete...- Blow to Glenmark: Delhi High Court restrains it from making Zita & Zita-MetHC restrained Glenmark from making, selling, advertising, distributing or exporting its anti-diabetes drugs Zita and Zita-Met.
- High Court restrains Glenmark Pharmaceuticals from business of anti-diabetes drugsEarlier, in an interim order, a division bench of the high Court had restrained Glenmark from making or selling its drug, used for treatmen...
- Supreme Court restrains Glenmark from producing anti-diabetes medicinesThe apex court allowed Glenmark Pharmaceuticals to continue selling existing stock of its anti-diabetes drugs Zita and Zita-Met in the mark...
- Glenmark Pharmaceuticals down over 4 per cent; m-cap erodes by Rs 1,015 croreShares of Glenmark Pharmaceuticals lost 4.51 per cent after high court barred it from making, marketing or selling its anti-diabetes medici...
- Glenmark Pharma falls 5% intraday after court injunction on two drugsGlenmark slipped 5% in trade on Monday, after Delhi high court restrained the company from manufacturing and marketing anti-diabetes drug.
- Sensex rallies over 100 points, Nifty tests 8600 levels; ten stocks in focus in Monday's tradeThe S&P BSE Sensex rallied as much as 124 points in trade on Monday, following positive trend seen in other Asian markets.
- High Court strived in 2013 to make Delhi safer place for womenThe high court, which took a bold step by throwing open the gangrape trial for national and international media is now hearing on day-to-da...
- MSD-Glenmark drug patent row: Delhi High Court reserves verdictThe Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.
- Delhi High Court seeks Glenmark's response on US drug giant MSD's appealJustice S Ravindra Bhat and SK Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm's plea challenging the sing...
- Drug patent row: Delhi High Court seeks Glenmark's response by May 22The American drug major is involved in a patent row with Glenmark which has recently come out with the two medicines in alleged violation o...
- Drug patent row: HC to hear plea of US firm on April 12A bench of justices Sanjay Kishan Kaul and Indermeet Kaur took the plea of US pharma major on record and posted it for hearing before anoth...
- Drug patent row: Merck Sharp and Dohme files appeal against interim order in row with GlenmarkMSD has filed an appeal before the Delhi HC challenging its single bench order refusing to grant interim relief to it on a patent row again...
- No interim relief to Merck against Glenmark’s diabetes genericsDelhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe court's order came on MSD's plea alleging that the Indian pharma company has violated its intellectual property right (IPR) over its an...
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-...
- Merck unit sues Glenmark Pharmaceuticals for infringing patent on diabetes drugsA unit of US drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
Load More
